15 active not recruiting. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Active not recruiting 15 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dymista in Chinese Adolescents Treatment with 137 µg azelastine hydrochloride and 50 μg of fluticasone propionate - Allergic Rhinitis Due to Allergens | Phase 4 | Active not recruiting | Viatris Inc. | 100 | 2026-05-08 | 2026-09-29 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma dupilumab, Matching Placebo, ICS/LABA - Asthma | Phase 4 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-08-26 | 2026-05-22 |
| Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care Albuterol and budesonide inhalation aerosol - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 1511 | 2024-05-10 | 2026-07-16 |
| Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 1358 | 2024-04-16 | 2026-10-06 |
| The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System - Asthma, COPD | Phase 4 | Active not recruiting | University of California, San Francisco | 40 | 2024-04-09 | 2026-08-13 |
| REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study Mepolizumab, Spirometry - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 336 | 2024-03-20 | 2025-08-01 |
| Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks Mepolizumab Injection, Functional Endoscopic Sinus Surgery (FESS). - Chronic Rhinosinusitis with Nasal Polyps, Asthma | Phase 4 | Active not recruiting | Vibeke Backer | 58 | 2023-04-01 | 2025-03-30 |
| Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month - Asthma | Phase 4 | Active not recruiting | Hospices Civils de Lyon | 20 | 2023-03-09 | 2024-11-18 |
| INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION Fluticasone propionate nasal spray, Fluticasone propionate-azelastine nasal spray - Allergic Rhinitis | Phase 4 | Active not recruiting | Pamukkale University | 61 | 2022-12-01 | 2026-02-17 |
| An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis Mycophenolate Mofetil plus prednisolone, Prednisolone - Hypersensitivity Pneumonitis | Phase 4 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 144 | 2022-11-23 | 2026-06-03 |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Sanofi | 1339 | 2021-12-16 | 2026-04-16 |
| Investigating Dupilumab's Effect in Asthma by Genotype Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Boston Children's Hospital | 150 | 2021-09-08 | 2026-02-23 |
| Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease Montelukast, Placebo - Meniere Disease, Allergic Rhinitis | Phase 4 | Active not recruiting | House Ear Institute | 39 | 2021-06-07 | 2025-03-18 |
| Epigenetic Health Benefits of Budesonide Budesonide Nasal, Placebo - Epigenetic Effects of Intranasal Steroids, Environmental Exposure | Phase 4 | Active not recruiting | University of British Columbia | 20 | 2021-01-07 | 2025-03-27 |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Benralizumab, Placebo - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 75 | 2019-10-08 | 2026-09-25 |
Asthma (10) · Rhinitis, Allergic (4) · Alveolitis, Extrinsic Allergic (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Meniere Disease (1) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Eosinophilia (1) · Vertigo (1)
Hypersensitivity (15) · Hypersensitivity, Immediate (15) · Immune System Diseases (15) · Respiratory Tract Diseases (15) · Bronchial Diseases (10) · Lung Diseases (10) · Lung Diseases, Obstructive (10) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Rhinitis (4) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1) · Disease Attributes (1) · Ear Diseases (1)
dupilumab (3) · mepolizumab (3) · Fluticasone (2) · Acetylcysteine (1) · Albuterol (1) · Budesonide (1) · Methods (1) · Mycophenolic Acid (1) · N-monoacetylcystine (1) · Prednisolone (1) · Propionates (1) · Therapeutics (1) · azelastine (1) · benralizumab (1) · fluticasone furoate (1)
AstraZeneca (2) · GlaxoSmithKline (2) · Boston Children's Hospital (1) · Hospices Civils de Lyon (1) · House Ear Institute (1) · Pamukkale University (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Regeneron Pharmaceuticals (1) · Sanofi (1) · University of British Columbia (1) · University of California, San Francisco (1) · Viatris Inc. (1) · Vibeke Backer (1)
United States (9) · Canada (6) · China (3) · Denmark (3) · Belgium (2) · France (2) · Germany (2) · India (2) · Japan (2) · Poland (2) · Puerto Rico (2) · South Korea (2) · Taiwan (2) · Turkey (Türkiye) (2) · United Kingdom (2)
Christopher Carlsten, MD (1) · Duc Tung Nguyen, Dr. (1) · Gilles Devouassoux, Pr (1) · John Fahy, MD, MS (1) · Mario Castro, MD (1) · Mary J Derebery, MD (1) · Sahajal Dhooria, MD, DM (1) · Vibeke B Backer, Professor (1) · Wanda Phipatanakul, MD, MS (1)
PMID 36891077, PMID 41759721, PMID 42474701, PMID 42742633
2018 (1), 2023 (1), R01HL080414 (1), U01AI143514 (1)